scroll to top
0
Press enter or spacebar to select a desired language.
Press enter or spacebar to select a desired language.
Your source for trusted research content

EBSCO Auth Banner

Let's find your institution. Click here.

Advanced Search Results For "Alejandro Moreno Puertas"

1 - 10 of 242 results for
 "Alejandro Moreno Puertas"
Press enter or spacebar to adjust the number of results displayed.

RAFAEL HUMBERTO MORENO-DURÁN Y RAFAEL GUTIÉRREZ GIRARD OT: LA CORRESPONDENCIA DE UN ESCRITOR Y SU CRÍTICO LITERARIO. (Spanish)

Publication Type: Periodical

Source(s): Estudios de Literatura Colombiana; ene-jun2022, Issue 50, p87-105, 19p

Abstract: Copyright of Estudios de Literatura Colombiana is the property of Universidad de Antioquia, Facultad de Comunicaciones and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written...

“DUEÑO” DEL PRI: “ALITO” DECIDIRÁ CANDIDATURAS Y ALIANZAS PARA 2023 Y 2024. (Spanish)

Publication Type: Periodical

Source(s): Proceso; 12/25/2022, Issue 2408, p19-22, 4p, 3 Color Photographs

Authors:

Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

Publication Type: Periodical

Source(s): The Lancet HIV; August 2020, Vol. 7 Issue: 8 pe565-e573, 9p

Abstract: A low CD4/CD8 ratio during antiretroviral therapy (ART) identifies people with heightened immunosenescence and increased risk of mortality. We aimed to assess the effects of integrase strand transfer inhibitor (INSTI)-based, protease inhibitor-based, o...

Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults

Publication Type: Periodical

Source(s): Med; November 2022, Vol. 3 Issue: 11 p760-773.e5

Abstract: SOBERANA 02 has been evaluated in phase I and IIa studies comparing homologous versus heterologous schedule (this one, including SOBERANA Plus). Here, we report results of immunogenicity, safety, and reactogenicity of SOBERANA 02 in a two- or three-dos...

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Publication Type: Periodical

Source(s): The Lancet; July 2019, Vol. 394 Issue: 10193 p121-130, 10p

Abstract: Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A1c(HbA1c) concentrations. We assessed the effect of the GLP-1 re...

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Publication Type: Periodical

Source(s): The Lancet; July 2019, Vol. 394 Issue: 10193 p131-138, 8p

Abstract: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-term effect of the GLP-1 receptor agonist dulaglutide on renal outcomes in an explorato...

Factores asociados al mal control de la anticoagulación con antivitaminaK en pacientes con fibrilación auricular no valvular atendidos en consultas de Medicina Interna y Neurología. Estudio ALADIN

Publication Type: Periodical

Source(s): Revista Clínica Española; October 2018, Vol. 218 Issue: 7 p327-335, 9p

Abstract: Identificar los factores asociados con el mal control de la anticoagulación con antagonistas de la vitaminaK (AVK) en pacientes con fibrilación auricular no valvular (FANV) atendidos en consultas de Neurología y Medicina Interna de España.

ALITO, TRAS EL CONSEJO NACIONAL DEL PRI: CONTROL TOTAL, CON “EL PODER DE SU FIRMA”. (Spanish)

Publication Type: Periodical

Source(s): Proceso; 5/14/2023, Issue 2428, p25-27, 3p, 3 Color Photographs

sponsored